Galectin Therapeutics, Inc. (GALT) Starts Presentation at LD Micro Conference

Galectin Therapeutics, Inc. develops therapeutics that target galectin proteins to treat fibrosis and cancer. The company is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on its unique understanding of galectin proteins, key mediators of biologic function. The company is leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. For more information, visit the company’s website at www.galectintherapeutics.com.